938440-64-3 | (5-(2-((2R,6S)-2,6-Dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol

938443-23-3    908142-03-0   

KU-63794 

[1]Patent:WO2007/60404,2007,A1.Locationinpatent:Page/Pagecolumn61-62

938440-64-3    938443-29-9 

[1]Pike,KurtG.;Malagu,Karine;Hummersone,MarcG.;Menear,KeithA.;Duggan,HeatherM.E.;Gomez,Sylvie;Martin,NiallM.B.;Ruston,Linette;Pass,SarahL.;Pass,Martin[BioorganicandMedicinalChemistryLetters,2013,vol.23,#5,p.1212-1216]

[2]CurrentPatentAssignee:ASTRAZENECAPLC-WO2007/60404,2007,A1Locationinpatent:Page/Pagecolumn88-89

38496-18-3    938440-64-3 

[1]Pike,KurtG.;Malagu,Karine;Hummersone,MarcG.;Menear,KeithA.;Duggan,HeatherM.E.;Gomez,Sylvie;Martin,NiallM.B.;Ruston,Linette;Pass,SarahL.;Pass,Martin[BioorganicandMedicinalChemistryLetters,2013,vol.23,#5,p.1212-1216]

64321-24-0   

KU-63794 

[1]BioorganicandMedicinalChemistryLetters,2013,vol.23,p.1212-1216

938443-19-7   

KU-63794 

[1]BioorganicandMedicinalChemistryLetters,2013,vol.23,p.1212-1216

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Journal: Bioorganic & medicinal chemistry letters 20130301

Title: Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Journal: Oncotarget 20120801

Title: Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.

Journal: The Journal of biological chemistry 20120706

Title: Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.

Journal: Molecular cancer research : MCR 20120601

Title: The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.

Journal: British journal of cancer 20120410

Title: Quantitative visualization of autophagy induction by mTOR inhibitors.

Journal: Methods in molecular biology (Clifton, N.J.) 20120101

Title: Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

Journal: Methods in molecular biology (Clifton, N.J.) 20120101

Title: Mechanical regulation of glycogen synthase kinase 3β (GSK3β) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein.

Journal: The Journal of biological chemistry 20111111

Title: The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.

Journal: Biochemical and biophysical research communications 20110422

Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Journal: Journal of medicinal chemistry 20110310

Title: The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

Journal: Bioorganic & medicinal chemistry letters 20091015

Title: Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Journal: The Biochemical journal 20090701

Title: Garcia-Martinez et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem.J. (2009)421 29.

Title: Collak FK, et al. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.J Biol Chem. 2012 Jul 6;287(28):23698-709. E

Title: Haagensen EJ, et al. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer. 2012 Apr 10;106(8):1386-94.